Kartos Therapeutics, Inc. (a Delaware corporation)
Kartos Therapeutics is a clinical stage biopharmaceutical company dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer. Kartos is developing a potential best-in-class oral MDM2 inhibitor (navtemadlin) for the treatment of patients with Myelofibrosis.